Phase 3 ELOQUENT-2 study: Extended four year follow-up (FU) of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).

被引：4
|
作者：
Lonial, Sagar
Dimopoulos, Meletios A.
Weisel, Katja C.
White, Darrell
Moreau, Philippe
Mateos, Maria-Victoria
Miguel, Jesus San
Anderson, Kenneth Carl
Shpilberg, Ofer
Grosicki, Sebastian
Spicka, Ivan
Walter-Croneck, Adam
Magen, Hila
Belch, Andrew
Reece, Donna Ellen
Beksac, Meral
Mekan, Sabeen
Sy, Oumar
Singhal, Anil K.
Richardson, Paul G.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.8028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8028
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis
    K Suzuki
    K Sunami
    K Ohashi
    S Iida
    T Mori
    H Handa
    K Matsue
    M Miyoshi
    E Bleickardt
    M Matsumoto
    M Taniwaki
    Blood Cancer Journal, 2017, 7 : e540 - e540
  • [22] Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
    Meletios A. Dimopoulos
    Sagar Lonial
    Darrell White
    Philippe Moreau
    Katja Weisel
    Jesus San-Miguel
    Ofer Shpilberg
    Sebastian Grosicki
    Ivan Špička
    Adam Walter-Croneck
    Hila Magen
    Maria-Victoria Mateos
    Andrew Belch
    Donna Reece
    Meral Beksac
    Andrew Spencer
    Heather Oakervee
    Robert Z. Orlowski
    Masafumi Taniwaki
    Christoph Röllig
    Hermann Einsele
    Morio Matsumoto
    Ka Lung Wu
    Kenneth C. Anderson
    Ying-Ming Jou
    Alex Ganetsky
    Anil K. Singhal
    Paul G. Richardson
    Blood Cancer Journal, 10
  • [23] Durable progression-free survival benefit in early responders to elotuzumab plus lenalidomide and dexamethasone (ELd): analysis of ELOQUENT-2 4-year data in relapsed/refractory (RR) multiple myeloma (MM)
    Scheid, C.
    Roellig, C.
    Weisel, K.
    Salwender, H-J
    Gramatzki, M.
    Edmaier-Schroeger, K.
    Sy, O.
    Goldschmidt, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 189 - 189
  • [24] Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study
    Dimopoulos, Meletios A.
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    LeBlanc, Richard
    Suzuki, Kenshi
    Raab, Marc S.
    Richardson, Paul G.
    McKiver, Mihaela Popa
    Jou, Ying-Ming
    Shelat, Suresh G.
    Robbins, Michael
    Rafferty, Brian
    San-Miguel, Jesus
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E164 - E165
  • [25] Elotuzumab plus bortezomib and dexamethasone (EBd) versus bortezomib and dexamethasone (Bd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)-2-year follow-up
    Palumbo, A.
    Offidani, M.
    Pegourie, B.
    De La Rubia, J.
    Garderet, L.
    Laribi, K.
    Bosi, A.
    Marasca, R.
    Laubach, J.
    Mohrbacher, A.
    Carella, A. M.
    Singhal, A. K.
    Lynch, M.
    Jou, Y-M
    Jakubowiak, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 28 - 28
  • [26] Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
    Dimopoulos, Meletios A.
    Lonial, Sagar
    White, Darrell
    Moreau, Philippe
    Weisel, Katja
    San-Miguel, Jesus
    Shpilberg, Ofer
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen, Hila
    Mateos, Maria-Victoria
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Spencer, Andrew
    Oakervee, Heather
    Orlowski, Robert Z.
    Taniwaki, Masafumi
    Roellig, Christoph
    Einsele, Hermann
    Matsumoto, Morio
    Wu, Ka Lung
    Anderson, Kenneth C.
    Jou, Ying-Ming
    Ganetsky, Alex
    Singhal, Anil K.
    Richardson, Paul G.
    BLOOD CANCER JOURNAL, 2020, 10 (09)
  • [27] Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up
    Palumbo, Antonio
    Offidani, Massimo
    Pegourie, Brigitte
    De La Rubia, Javier
    Garderet, Laurent
    Laribi, Kamel
    Bosi, Alberto
    Marasca, Roberto
    Laubach, Jacob P.
    Mohrbacher, Ann
    Carella, Angelo Michele
    Singhal, Anil K.
    Lynch, Mark
    Jou, Ying-Ming
    Jakubowiak, Andrzej
    BLOOD, 2015, 126 (23)
  • [28] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
    Nizar J. Bahlis
    Meletios A. Dimopoulos
    Darrell J. White
    Lotfi Benboubker
    Gordon Cook
    Merav Leiba
    P. Joy Ho
    Kihyun Kim
    Naoki Takezako
    Philippe Moreau
    Jonathan L. Kaufman
    Maria Krevvata
    Christopher Chiu
    Xiang Qin
    Linda Okonkwo
    Sonali Trivedi
    Jon Ukropec
    Ming Qi
    Jesus San-Miguel
    Leukemia, 2020, 34 : 1875 - 1884
  • [29] Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
    Bahlis, Nizar J.
    Dimopoulos, Meletios A.
    White, Darrell J.
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Kaufman, Jonathan L.
    Krevvata, Maria
    Chiu, Christopher
    Qin, Xiang
    Okonkwo, Linda
    Trivedi, Sonali
    Ukropec, Jon
    Qi, Ming
    San-Miguel, Jesus
    LEUKEMIA, 2020, 34 (07) : 1875 - 1884
  • [30] Safety and Efficacy of Elotuzumab with Lenalidomide/Dexamethasone for Multiple Myeloma in a Japanese Subpopulation Analysis of the Phase 3 Eloquent-2 Trial
    Ohashi, Kazuteru
    Suzuki, Kenshi
    Sunami, Kazutaka
    Iida, Shinsuke
    Okamoto, Shinichiro
    Handa, Hiroshi
    Matsue, Kosei
    Miyoshi, Masafumi
    Bleickardt, Eric
    Matsumoto, Morio
    Taniwaki, Masafumi
    BLOOD, 2016, 128 (22)
12345